This article was originally published in The Gray Sheet
Executive SummaryNext-generation vascular closure device gains FDA market go-ahead for use in minimally invasive closure of femoral artery access sites following diagnostic procedures such as coronary angioplasty. Made by Abbott's newly acquired Perclose unit, the Closer takes "less than half the time" of current Perclose closure devices
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.